Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DiaKine Therapeutics, a start-up biopharmaceutical company, has announced encouraging results from a preclinical study involving its lead drug candidate Lisofylline. The results indicated that the compound may reduce two key risk factors for type 2 diabetes.
Subscribe to our email newsletter
According to the company, the study results showed a reduced macrophage content in the fat tissue of Lisofylline (LSF)-treated mice, when compared to controls, indicating its immune modulating action. Results also showed improved insulin action in glucose and insulin tolerance tests in LSF-treated mice.
LSF was shown to increase insulin action and reduce the level of inflammatory cells in fat tissue of mice fed diets high in polyunsaturated or saturated fats, according to the study conducted by the Garvan Institute of Medical Research in Sydney, Australia.
LSF is a synthetic small molecule with novel anti-inflammatory properties that has been shown to block autoimmune damage to insulin producing cells and to improve insulin action in type 2 diabetes. Lisofylline has also demonstrated that it can effectively prevent type 1 diabetes in preclinical models, the company said.
Jerry Nadler, chairman, and chief science officer of DiaKine Therapeutics, said: The results are quite exciting and indicate that LSF, and related DiaKine small molecule therapies, could play a significant part in treating type 2 diabetes by reducing inflammation and improving insulin action.
The study results complement our earlier findings, and point toward a much broader role for DiaKine’s drugs in reducing the factors that cause type 1 and type 2 diabetes.